Sophie McGrath is a partner in Goodwin’s Technology and Life Sciences group. Ms. McGrath focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams. She advises on a wide range of corporate matters, including private and public financings, mergers and acquisitions, public offerings and restructurings.

Ms. McGrath also has a keen interest in the impact investment sector, acting for both investors and companies that are targeting a “double bottom line,” either through environmental or social impact, and is a member of the British Venture Capital Association’s Impact Investment advisory group, which has a mandate to promote the development of the impact investment sector in the UK.

Ms. McGrath is a recommended lawyer for Chambers UK and Legal 500. She is described by Chambers as “a venture capital expert” who serves as a “fantastic adviser” to both investor and company clients. She applies her “very commercial” approach to deals in the life sciences and technology sectors.”

Prior to joining Goodwin in 2018, Ms. McGrath was a partner at Brown Rudnick.





  • Advised Achilles Therapeutics, a Stevenage-based biopharmaceutical company developing personalised cancer immunotherapies, on the completion of its £100 million Series B financing, which is one of the largest growth stage venture rounds for a UK biotech company in 2019.
  • Advised Quanta Dialysis Technologies Limited, a medical device company focused on haemodialysis systems for use in the clinic and home, on the closing of its Series C funding round raising over £38 million.
  • Advised Advanced Medical Solutions Group plc, an AIM listed life sciences company, on its acquisition of Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform.
  • Advised Novastar Ventures Limited, an impact investment fund, on its Series A investment in The Sure Chill Company Limited, a company that develops a revolutionary platform cooling technology.
  • Advised N+1 Singer as nominated adviser and broker to Verona Pharma plc, a listed drug development company, in relation to its £44.7 million UK and U.S. placing.*
  • Advised Novo A/S, Lundbeckfond A/S, F-Prime and Gilde Heathcare Partners B.V. on multiple financing rounds into Acacia Pharma Group Limited and on its ultimate listing on Euronext, Brussels.
  • Advised Cruncher Technologies Limited, a company using artificial intelligence to solve big data issues for the financial markets, on various financing rounds and its commercialisation into the U.S.*
  • Advised Gilde Healthcare Partners B.V. as lead investor on multiple financing rounds into Lumeon Limited, a digital healthcare company.*
  • Advised Mustard Seed, an impact investment fund, on multiple investments including:*
    • Skin Healthcare, a skin analytics app and device designed to help identify early signs of skin cancer
    • Beulah, a luxury goods company providing employment opportunities to victims of human trafficking
    • Switchee, a company seeking to significantly reduce energy use and spending

* Denotes experience prior to joining Goodwin.

Professional Activities

British Venture Capital Association


Ms. McGrath has extensive experience in private investment work, acting for companies at all stages of development, as well as investors and management teams. She is a recommended lawyer in Chambers UK 2020 in the field ‘Private Equity: Venture Capital Investment.

Ms. McGrath has also has been ranked by Legal 500 for Venture Capital since 2013 and in 2017 for M&A: Smaller Deals, up to £50 million and is described as “very resourceful and knowledgeable.”

In The News









Qualified Lawyers Transfer Test, 2003
College of Law London
Graduate Diploma in Law, 1999
College of Law, Sydney
Bachelors in Commerce and Laws, 1998
University of Sydney



Solicitor of the Senior Courts of England and Wales
New South Wales, Australia
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique